PR Newswire (Fri, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,764 people get CLSN articles and Market Currents by email alert.
Get email alerts on CLSN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
PR Newswire (May 9, 2013)
-
-
-
-
PR Newswire (Apr 23, 2013)
-
-
-
-
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 12, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
Celsion's CEO Discusses Q3 2012 Results - Earnings Call TranscriptMon, Nov 12, 2012
-
Celsion Management Discusses Q2 2012 Results - Earnings Call TranscriptTue, Aug 14, 2012
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 22, 2013)
-
PR Newswire (Jan 31, 2013)
-
at MarketWatch.com (Jan 15, 2013)
-
Marketwire (Nov 12, 2012)
-
Marketwire (Nov 6, 2012)
CLSN vs. ETF Alternatives
Company Description
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 17, 9:08 AM Celsion (CLSN) jumps 14% premarket after the company says data from a Phase III HEAT study suggests ThermoDox combined with radio frequency ablation warrants "further investigation and development … as a first line treatment for hepatocellular carcinoma." (PR) 1 Comment [Healthcare, On the Move]
- Thursday, May 9, 9:39 AM Celsion (CLSN): Q1 EPS of -$0.12 beats by $0.04. Revenue of $125K misses by $65.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 23, 9:03 AM Celsion Corp (CLSN) is moving higher in pre-trading on comments from the company that its experimental cancer drug, Thermodox, shows it may now in fact be viable for the treatment of liver cancer. The comments come just months after the company warned of the drug's limited prospects, causing the stock to crater 81% in one day in January after the company suggested the drug failed to significantly slow the progression of liver cancer in a late-stage trial. Shares +14%. 1 Comment [Healthcare, On the Move, Global & FX]
-
Monday, March 18, 9:10 AM
Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move] -
Friday, March 8, 9:10 AM
Premarket gainers: P +25%. TPX +9%. BVSN +7%. ANN +8%. CLSN +5%. HRB +5%.
Losers: SKUL -17%. MXWL -15%. MED -9%. GOL -6%. Comment! [On the Move] -
Tuesday, February 12, 12:45 PM
Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move] -
Monday, February 11, 9:15 AM
Premarket gainers: CLSN +9%. AUDC +7%.
Losers: NVO -14%. RDN -7%. CZR -7%. HEK -5%.
1 Comment [On the Move] -
Monday, February 4, 12:45 PM
Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move] - Monday, February 4, 12:33 PM Celsion (CLSN -11.4%) sinks again today after noting in a SEC filing that it's entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell $25M worth of shares, from time to time. The stock cratered last week on news that its liver cancer drug TheromDox had failed its latest clinical trials. 2 Comments [Healthcare, On the Move]
- Friday, February 1, 4:39 PM Shares of Celsion (CLSN) added to yesterday's 79% free fall today, closing out the day with an additional 12.6% hit after touching a new 52-week low of $1.25 earlier. The downturn was sparked on Thursday after the company announced that ThermoDox did not meet the primary endpoint in a Phase III study in patients with hepatocellular carcinoma also known as primary liver cancer. 4 Comments [Healthcare, On the Move]
-
Friday, February 1, 12:45 PM
Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move] -
Friday, February 1, 9:10 AM
Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move] - Thursday, January 31, 3:18 PM Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral on the back of the failed trial results on its experimental liver cancer drug ThermoDox. The technology failed to significantly slow the progression of liver cancer by what appears to be a wide marging, and calls into doubt the drug's near-term viability. 1 Comment [Healthcare, On the Move]
-
Thursday, January 31, 12:45 PM
Midday top 10 gainers: ORCC +82%. WMS +52%. FTNT +24%. HHS +22%. EDMC +18%. BTUI +18%. JDSU +18%. PBI +17%. CSII +16%. SGI +16%.
Midday top 10 Losers: CLSN -81%. LQDT -24%. STZ -20%. NVGN -18%. FIO -16%. HALO -16%. RDEN -14%. USAK -13%. HAR -13%. JBSS -12%. Comment! [On the Move] - Thursday, January 31, 9:23 AM Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with primary liver cancer. The study was designed to show a 33% improvement in progression-free survival. CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox. 5 Comments [Healthcare, On the Move]
-
Thursday, January 31, 9:13 AM
Premarket gainers: ORCC +82%. WMS +55%. FTNT +20%. SGMS +15%. JDSU +14%. KERX +14%. ALGN +13%. SWKS +13%. CTXS +12%. ERIC +11%. DCTH +7%. PBI +8%. QCOM +6%. ALU +6%. CXS +6%. FNSR +6%. LVS +6%. UA +5%. IGT +5%.
Losers: CLSN -79%. LQDT -15%. FIO -14%. RIMM -7%. AFFY -7%. RMD -6%. FB -6%. VNR -5%. 1 Comment [On the Move]
-
Quoth the Raven
Celsion's support around .95 seems to be the real deal. $CLSN $SPY http://seekingalpha.com/a/usbh - View all 2 replies
-
-
-
- View all 0 replies
-
Quoth the Raven
Insiders are buying Celsion $CLSN on the open market at .92, so am I. http://bit.ly/15wDowJ - View all 1 replies
-
RSI Raistlin: CLSN seems sketchy though after fail and cash burn. Plus a 3.3% increase in holdings and under $5k worth of stock isn't a strong statement.
-
- View all 0 replies
-
Quoth the Raven
Can $CLSN make the run to 1.50 on earnings this week? http://seekingalpha.com/a/tsbn - View all 0 replies
-
Quoth the Raven
The Celsion $CLSN bull in me is coming alive again. Earnings this Wednesday! http://seekingalpha.com/a/tsbn - View all 2 replies
-
-
Quoth the Raven: My $1 calls did great. I'm going to hold through earnings.
-
- View all 0 replies
-
- View all 5 replies
-
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
-
-
- View all 0 replies
-
- View all 4 replies
-
joeg1969: Definetly !!!!!!!!!!!!Willl see how things play out for a bit before adding .......
-
LATEST REPLIES
-
Quoth the Raven
Celsion's support around .95 seems to be the real deal. $CLSN $SPY http://seekingalpha.com/a/usbh - View all 2 replies
-
-
-
Quoth the Raven
Insiders are buying Celsion $CLSN on the open market at .92, so am I. http://bit.ly/15wDowJ - View all 1 replies
-
RSI Raistlin: CLSN seems sketchy though after fail and cash burn. Plus a 3.3% increase in holdings and under $5k worth of stock isn't a strong statement.
-
- View all 5 replies
-
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
-
-
Quoth the Raven
The Celsion $CLSN bull in me is coming alive again. Earnings this Wednesday! http://seekingalpha.com/a/tsbn - View all 2 replies
-
-
Quoth the Raven: My $1 calls did great. I'm going to hold through earnings.
-
- View all 4 replies
-
joeg1969: Definetly !!!!!!!!!!!!Willl see how things play out for a bit before adding .......
-
-
- View all 5 replies
-
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
-
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50
-
- View all 10 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 14 replies
-
Nick Chiu: Thumpy, that is a good bet for volatility collapse and works well if CLSN stays or goes up..
-
-
angrygiraffe
If $CLSN is going to either drop to $1 or less or shoot up to $20+, why not just straddle with short+calls? Am I missing something? - View all 3 replies
-
angrygiraffe: True. I guess I'm just wondering how accurate these predictions are. I can see the low end being the case. Not sure about high end.
-
noueis: Right now the premiums are so large that a drop wouldn't net you much. You would have to get below a dollar just to break even
-
- View all 7 replies
-
JMattius: Agreed. I will watch closely on the 26th. I jumped in today so hopefully she still has some room to run. Have a merry Christmas.
-
-
biomanbaba
SHORT MEDIA CAMPAIGN under way..it is design to strike unwarranted FEAR into the minds of $CLSN shareholders DONT LET THEM TAKE YOUR MONEY - View all 1 replies
-
Avoc: Though, I welcome the cheaper shares. If it goes under 7.50 I will be adding.
-
- View all 1 replies
-
biomanbaba: SHORT MEDIA CAMPAIGN under way...it is design to strike unwarranted FEAR into the minds of CLSN shareholders DONT LET THEM TAKE YOUR MONEY
-
- View all 23 replies
-
-